Schaeffers Investment Research·2026-02-03 16:04Company Performance - Pfizer Inc (NYSE:PFE) shares decreased by 3.2%, trading at $25.40, despite exceeding earnings and revenue expectations for Q4 [1] - The company is facing weak demand for its Covid-19 vaccine and has reaffirmed a lackluster outlook for 2026 [1] - Merck & Co Inc (NYSE:MRK) reported profits of $2.04 per share on sales of $16.4 billion, surpassing analysts' estimates for Q4, with shares up 2.5% to $116.19 [3] Market Trends - Pfizer's stock is experiencing overhead pressure near the $27 level, limiting gains since November, and is on track to end a three-day winning streak with its worst loss since December [2] - Merck is on track to achieve its fourth consecutive win, having surged to its highest level since September, with a notable 46.8% nine-month lead [3] Options Activity - Put volume for Pfizer is running at double the intraday average, with the February 24 put being the most popular option [4] - Merck is also seeing double the overall options volume typically observed, with the 110 call in the same series leading the way [4]